PROQR THERAPEUTICS NV (PRQR)
NL0010872495 - Common Stock
We assign a fundamental rating of 2 out of 10 to PRQR. PRQR was compared to 561 industry peers in the Biotechnology industry. PRQR may be in some trouble as it scores bad on both profitability and health. PRQR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRQR had negative earnings in the past year.
In the past year PRQR has reported a negative cash flow from operations.
In the past 5 years PRQR always reported negative net income.
In the past 5 years PRQR reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -22.41%, PRQR is doing good in the industry, outperforming 74.59% of the companies in the same industry.
Looking at the Return On Equity, with a value of -95.83%, PRQR is in line with its industry, outperforming 46.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.41% | ||
| ROE | -95.83% | ||
| ROIC | N/A |
ROA(3y)-29.27%
ROA(5y)-36.61%
ROE(3y)-73.83%
ROE(5y)-72.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRQR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRQR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRQR has more shares outstanding
The debt/assets ratio for PRQR is higher compared to a year ago.
2.2 Solvency
PRQR has an Altman-Z score of -3.43. This is a bad value and indicates that PRQR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.43, PRQR perfoms like the industry average, outperforming 44.14% of the companies in the same industry.
PRQR has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.46, PRQR is not doing good in the industry: 72.97% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.43 |
ROIC/WACCN/A
WACC6.94%
2.3 Liquidity
A Current Ratio of 2.33 indicates that PRQR has no problem at all paying its short term obligations.
The Current ratio of PRQR (2.33) is worse than 72.97% of its industry peers.
PRQR has a Quick Ratio of 2.33. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
PRQR has a Quick ratio of 2.33. This is in the lower half of the industry: PRQR underperforms 71.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.33 |
3. Growth
3.1 Past
PRQR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.09%, which is quite impressive.
The Revenue has grown by 361.41% in the past year. This is a very strong growth!
Measured over the past years, PRQR shows a quite strong growth in Revenue. The Revenue has been growing by 10.58% on average per year.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
Revenue 1Y (TTM)361.41%
Revenue growth 3Y0.26%
Revenue growth 5Y10.58%
Sales Q2Q%180.51%
3.2 Future
The Earnings Per Share is expected to decrease by -15.05% on average over the next years. This is quite bad
The Revenue is expected to grow by 41.21% on average over the next years. This is a very strong growth
EPS Next Y10.29%
EPS Next 2Y-9.01%
EPS Next 3Y-15.05%
EPS Next 5YN/A
Revenue Next Year27.47%
Revenue Next 2Y7.67%
Revenue Next 3Y0%
Revenue Next 5Y41.21%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRQR. In the last year negative earnings were reported.
Also next year PRQR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as PRQR's earnings are expected to decrease with -15.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.01%
EPS Next 3Y-15.05%
5. Dividend
5.1 Amount
No dividends for PRQR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROQR THERAPEUTICS NV
NASDAQ:PRQR (1/6/2025, 4:07:54 PM)
2.62
-0.14 (-5.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners31.18%
Inst Owner Change0%
Ins Owners2.35%
Ins Owner ChangeN/A
Market Cap277.46M
Analysts83.08
Price Target8.5 (224.43%)
Short Float %0.4%
Short Ratio0.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.75%
Min EPS beat(2)7.09%
Max EPS beat(2)76.42%
EPS beat(4)3
Avg EPS beat(4)-157.39%
Min EPS beat(4)-732.51%
Max EPS beat(4)76.42%
EPS beat(8)7
Avg EPS beat(8)-72.25%
EPS beat(12)9
Avg EPS beat(12)-54.34%
EPS beat(16)11
Avg EPS beat(16)-41.02%
Revenue beat(2)0
Avg Revenue beat(2)-56.01%
Min Revenue beat(2)-65.98%
Max Revenue beat(2)-46.04%
Revenue beat(4)1
Avg Revenue beat(4)-32.9%
Min Revenue beat(4)-65.98%
Max Revenue beat(4)39.06%
Revenue beat(8)2
Avg Revenue beat(8)-26%
Revenue beat(12)6
Avg Revenue beat(12)-2.63%
Revenue beat(16)9
Avg Revenue beat(16)34.87%
PT rev (1m)24.53%
PT rev (3m)94.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.53%
EPS NY rev (1m)-7.36%
EPS NY rev (3m)-1.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)55.06%
Revenue NY rev (1m)-28.75%
Revenue NY rev (3m)-17.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.78 | ||
| P/tB | 10.78 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.21
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.41% | ||
| ROE | -95.83% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-29.27%
ROA(5y)-36.61%
ROE(3y)-73.83%
ROE(5y)-72.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 67.05% | ||
| Cap/Sales | 8.85% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.33 | ||
| Altman-Z | -3.43 |
F-Score4
WACC6.94%
ROIC/WACCN/A
Cap/Depr(3y)34.44%
Cap/Depr(5y)34.12%
Cap/Sales(3y)16.4%
Cap/Sales(5y)17.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.86%
EPS Next Y10.29%
EPS Next 2Y-9.01%
EPS Next 3Y-15.05%
EPS Next 5YN/A
Revenue 1Y (TTM)361.41%
Revenue growth 3Y0.26%
Revenue growth 5Y10.58%
Sales Q2Q%180.51%
Revenue Next Year27.47%
Revenue Next 2Y7.67%
Revenue Next 3Y0%
Revenue Next 5Y41.21%
EBIT growth 1Y29.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.27%
EBIT Next 3Y-32.45%
EBIT Next 5YN/A
FCF growth 1Y28.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.97%
OCF growth 3YN/A
OCF growth 5YN/A